Spectrum acquires Talon, plans late 2013 Marqibo launch
This article was originally published in Scrip
Executive Summary
Spectrum Pharmaceuticals acquired Talon Therapeutics for $11.3 million upfront, cancellation of outstanding debt and up to $195 million in milestone payments – although the latter is a risky bet for Talon shareholders based on projected Marqibo sales.